title: High-resolution contrast-enhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings.
abstract: OBJECTIVE
  The purpose of this work was to demonstrate susceptibility effects (SusE) in various types of brain tumors with 3T high-resolution (HR)-contrast-enhanced (CE)-susceptibility-weighted (SW)-MR imaging and to correlate SusE with positron-emission tomography (PET) and histopathology.
  
  
  METHODS
  Eighteen patients with brain tumors, scheduled for biopsy or tumor extirpation, underwent high-field (3T) MR imaging. In all of the patients, an axial T1-spin-echo (SE) sequence and an HR-SW imaging sequence before and after IV application of a standard dose of contrast agent (MultiHance) was obtained. Seven patients preoperatively underwent PET. The frequency and formation of intralesional SusE in all of the images were evaluated and correlated with tumor grade as determined by PET and histopathology. Direct correlation of SusE and histopathologic specimens was performed in 6 patients. Contrast enhancement of the lesions was assessed in both sequences.
  
  
  RESULTS
  High-grade lesions demonstrated either high or medium frequency of SusE in 90% of the patients. Low-grade lesions demonstrated low frequency of SusE or no SusE. Correlation between intralesional frequency of SusE and histopathologic, as well as PET, tumor grading was statistically significant. Contrast enhancement was equally visible in both SW and SE sequences. Side-to-side comparison of tumor areas with high frequency of SusE and histopathology revealed that intralesional SusE reflected conglomerates of increased tumor microvascularity.
  
  
  CONCLUSIONS
  3T HR-CE-SW-MR imaging shows both intratumoral SusE not visible with standard MR imaging and contrast enhancement visible with standard MR imaging. Because frequency of intratumoral SusE correlates with tumor grade as determined by PET and histopathology, this novel technique is a promising tool for noninvasive differentiation of low-grade from high-grade brain tumors and for determination of an optimal area of biopsy for accurate tumor grading.
authors: MR Centre of Excellence, Department of Radiology, Medical University Vienna, Vienna, Austria.
authors: K
authors: K
authors: Pinker
authors: I M
authors: IM
authors: Noebauer-Huhmann
authors: I
authors: I
authors: Stavrou
authors: R
authors: R
authors: Hoeftberger
authors: P
authors: P
authors: Szomolanyi
authors: G
authors: G
authors: Karanikas
authors: M
authors: M
authors: Weber
authors: A
authors: A
authors: Stadlbauer
authors: E
authors: E
authors: Knosp
authors: K
authors: K
authors: Friedrich
authors: S
authors: S
authors: Trattnig
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology; D003287:Contrast Media; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine
references: Cancer. 1985 Sep 1;56(5):1106-11
references: 2990664
references: Radiology. 2006 Mar;238(3):958-69
references: 16424238
references: Invest Radiol. 2006 Mar;41(3):249-55
references: 16481907
references: J Magn Reson Imaging. 2005 Oct;22(4):439-50
references: 16163700
references: Neuroradiology. 2002 Aug;44(8):656-66
references: 12185543
references: J Magn Reson Imaging. 2006 Jul;24(1):41-51
references: 16755540
references: J Clin Oncol. 2006 Mar 10;24(8):1273-80
references: 16525182
references: Eur Radiol. 2006 Jun;16(6):1280-7
references: 16508769
references: MAGMA. 1998 Aug;6(1):62-9
references: 9794291
references: Radiology. 1997 Feb;202(2):511-6
references: 9015082
references: Zentralbl Neurochir. 2006 May;67(2):55-66
references: 16673237
references: AJNR Am J Neuroradiol. 2005 Apr;26(4):736-42
references: 15814914
references: Expert Rev Neurother. 2005 Nov;5(6 Suppl):S33-9
references: 16274269
references: J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
references: 11895036
references: J Radiol. 2004 Nov;85(11):1901-8
references: 15602412
references: Invest Radiol. 2003 Jul;38(7):409-14
references: 12821854
references: Semin Radiat Oncol. 1998 Jul;8(3):197-207
references: 9634496
references: Radiology. 1997 Jul;204(1):272-7
references: 9205259
references: Curr Treat Options Oncol. 2001 Dec;2(6):495-506
references: 12057095
references: Invest Radiol. 2003 Jul;38(7):415-22
references: 12821855
references: Magn Reson Med. 2004 Sep;52(3):612-8
references: 15334582
references: Invest Radiol. 1999 Jun;34(6):427-34
references: 10353036
references: AJNR Am J Neuroradiol. 2004 May;25(5):756-60
references: 15140714
references: Neuroradiology. 2001 May;43(5):364-9
references: 11396739
references: NMR Biomed. 2001 Nov-Dec;14(7-8):453-67
references: 11746938
references: J Comput Assist Tomogr. 2000 Nov-Dec;24(6):949-57
references: 11105717
references: J Magn Reson Imaging. 1999 Aug;10(2):118-23
references: 10441013
references: NMR Biomed. 2001 Nov-Dec;14(7-8):478-83
references: 11746940
references: AJNR Am J Neuroradiol. 2002 Oct;23(9):1553-6
references: 12372746
references: AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98
references: 14625221
references: Rofo. 2005 Aug;177(8):1065-9
references: 16021537